Name: Chimeric Human IgG4-S228P Isotype Control Antibody
Brand: Syd Labs
SKU: PA007194
Price: 150.00 USD
Availability: InStock
Rating: 5 (10 reviews)

Catalog No.

Product Name

Size

List Price (US$)

Quantity

PA007194

In Vivo Grade Recombinant Chimeric Human IgG4-S228P Isotype Control Antibody

1 mg

150.00

PA007194

In Vivo Grade Recombinant Chimeric Human IgG4-S228P Isotype Control Antibody

5 mg

350.00

PA007194

In Vivo Grade Recombinant Chimeric Human IgG4-S228P Isotype Control Antibody

25 mg

900.00

PA007195

In Vivo Grade Recombinant Chimeric Human IgG4-S228P L235E P329G Isotype Control Antibody

1 mg

160.00

PA007195

In Vivo Grade Recombinant Chimeric Human IgG4-S228P L235E P329G Isotype Control Antibody

5 mg

525.00

PA007195

In Vivo Grade Recombinant Chimeric Human IgG4-S228P L235E P329G Isotype Control Antibody

25 mg

1350.00

Description

A chimeric human IgG4-S228P isotype control consists of murine variable regions and human IgG4-S228P constant regions. The recombinant chimeric human IgG4-S228P isotype control (chimeric IgG4-S228P kappa isotype control antibody) is produced in mammalian cells (CHO cells) like our other recombinant human IgG isotype control and mutant antibodies. The ideal recombinant chimeric human IgG4-S228P isotype control has low or no specific binding to any human sample.

PA007194: In Vivo Grade Recombinant Chimeric Human IgG4-S228P kappa Isotype Control Antibody (Chimeric IgG4-S228P Isotype Control)

The in vivo grade recombinant chimeric human IgG4-S228P kappa isotype control antibody (chimeric hIgG4-S228P isotype control) was produced in CHO cells.
Immunogen: N/A.
Clone: 4F17m.
Isotype: human IgG4, kappa.
Applications: an isotype-matched negative control for human IgG4 kappa antibodies used in ELISA, Western Blot (WB), Flow Cytometry (Flow), Immunoprecipitation (IP), Immunohistochemistry (Paraffin) (IHC (P)), Immunohistochemistry (Frozen) (IHC (F)), and in vivo animal model research.
Formulation: 0.2 μM filtered solution of 1x PBS.
Purity: >95% by SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU/mg of protein as determined by LAL method.

PA007195: In Vivo Grade Recombinant Chimeric Human IgG4-S228P L235E P329G kappa Isotype Control Antibody (Chimeric hIgG4-SPLEPG Isotype Control)

The in vivo grade recombinant chimeric human IgG4-S228P L235E P329G kappa isotype control antibody (chimeric hIgG4-SPLEPG isotype control) was produced in CHO cells.
Immunogen: N/A.
Clone: 4F17m.
Isotype: human IgG4, kappa.
Applications: an isotype-matched negative control for human IgG4 kappa antibodies used in ELISA, Western Blot (WB), Flow Cytometry (Flow), Immunoprecipitation (IP), Immunohistochemistry (Paraffin) (IHC (P)), Immunohistochemistry (Frozen) (IHC (F)), and in vivo animal model research.
Formulation: 0.2 μM filtered solution of 1x PBS.
Purity: >95% by SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU/mg of protein as determined by LAL method.

Shipping: The product is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
1 month from date of receipt, 2 to 8°C as supplied.
12 months from date of receipt, -20°C to -70°C as supplied.

References of Chimeric Human IgG4-S228P Isotype Control Antibody:

Safety, Tolerability, and Pharmacokinetics of PNT001, a Humanized IgG4 S228P Monoclonal Antibody Targeting Cis P-Tau231, in Healthy Volunteers: A First-in-Human Study
Luca, W., et al. Journal of Prevention of Alzheimer's Disease. 2024;11(1):227-235. doi: 10.14283/jpad.2024.25. PMID: 38374743
PNT001 is a humanized full-length IgG4 S228P monoclonal antibody that binds the cis isomer of the phosphorylated mid-domain Thr231-Pro232 motif in human full-length (2N4R) tau (cis-pT231 tau) with >1,000-fold selectivity for the cis isomer of pT231 compared to the trans isomer and high affinity for cis-pTau231 (KD = 0.3 nM, ca. 45 ng/mL). Extensive preclinical data indicate that the cis-conformer of tau that is phosphorylated at amino acid residue threonine-231 (cis-pT231 tau) has an important pathologic role in several tauopathies, including progressive supranuclear palsy (PSP), corticobasilar degeneration (CBD), Alzheimer’s disease (AD), and traumatic brain injury (TBI), and is therefore a plausible target for the treatment of both acute and chronic tauopathies. The primary objective of this study was to evaluate the safety and tolerability of single-escalating i.v. doses of PNT001 in healthy volunteers. The results of this first-in-human study of PNT001 showed a tolerable safety profile of PNT001 after a single dose in healthy volunteers over a dose range of 33–4,000 mg. A murine version of PNT001 containing identical complementarity in the determining regions to PNT001 (mPNT001) was tested in the Tg4510 mouse that overexpresses a pathologic, human mutant form of tau.
Tags: activity of Chimeric Human IgG4-S228P Isotype Control; Chimeric Human IgG4-S228P Isotype Control

Fc–Fc interactions and immune inhibitory effects of IgG4: implications for anti-PD-1 immunotherapies
Zhang, W., et al. Journal for Immunotherapy of Cancer. 2024 Jun 25;12(6):e009034. doi: 10.1136/jitc-2024-009034. PMID: 38925680
The Western blots demonstrate that biotin-labeled IgG4wt, nivolumab and IgG4 S 228P variant penpulimab demonstrate binding capability to immobilized IgG on the membranes (1 µg/well). The majority of anti-programmed cell-death 1 (PD-1) monoclonal antibodies (mAbs) use S 228P mutation IgG4 as the structural basis to avoid the activation of immune cells or complement. Fc-null IgG1 represents a safer choice for anti-PD-1 immunotherapies by avoiding both the adverse Fc–Fc interactions and Fc-related immune inhibitory effects of IgG4. Experiments demonstrated that wildtype IgG4 and nivolumab bound to immobilized IgG through Fc–Fc interactions, diminishing antibody-dependent cell-mediated cytotoxicity and phagocytosis reactions. This study provides a comprehensive evaluation of anti-PD-1 mAbs of these two frameworks.
Tags: human IgG1 recombinant isotype control; Chimeric Human IgG4-S228P Isotype Control antibody for cancer research

Impact of IgG subclass on molecular properties of monoclonal antibodies
Tang, Y., et al. mAbs. 2021 Nov 11;13(1):1993768. doi: 10.1080/19420862.2021.1993768. PMID: 34763607
Each series is comprised of IgG1, IgG1 L234A, L235E, G237A, A330S, P331S (IgG1EN), IgG2, and IgG4 S228P, L234A, L235A (IgG4PAA), resulting in a total of 12 antibodies. Over the past 20 years, monoclonal antibodies (mAbs) have become the most dominant biotherapeutics in the pharmaceutical industry. The high specificity, long half-life, and generally safe profiles have made antibodies attractive as human therapeutics. Among the antibody therapeutics marketed in the United States and Europe, ~90% (including antibody-drug conjugates) are IgG immunoglobulin and ~ 10% are either bispecific antibody, PEGylated antigen-binding fragments (Fabs), single-chain variable fragment (scFv), Fab, or nanobody. The IgG antibody family consists of IgG1, IgG2, IgG3, and IgG4 subclasses based on small differences in the constant region of the heavy chain (HC).
Tags: Chimeric Human IgG4-S228P Isotype Control antibody in vivo; Chimeric Human IgG4-S228P Isotype Control for animal model

A new approach to produce IgG4-like bispecific antibodies
Zhao, C., et al. Scientific Reports. 2021 Sep 10;11(1):18150. doi: 10.1038/s41598-021-97393-2. PMID: 34545109
We selected IgG 4 S228P as the development target (PDB: 5DK3) and analyzed the overlay crystal structures of CH1/CL and TCR Cα/Cβ (PDB: 3ARB) (Fig. 1A). Monoclonal antibodies are monospecific, can bind to only one antigen and have limited target specificity. However, bispecific antibodies, by design, can bind to two different antigens or two different epitopes of the same antigen to maximize the specificity, thereby greatly expanding therapeutic scope and potential 3. In this study, we used knob-into-hole technique to achieve heavy chain heterodimerization through enhancement of heavy and light chain pairing and formation of monovalent IgG-like bispecific antibody by partial replacement of CH1-CL interface with amino acids of TCR α/β constant domain interface. Biochemical, biophysical and functional characterization was carried out to profile a bispecific antibody against both PD-1 and LAG3.
Tags: function of Chimeric Human IgG4-S228P Isotype Control; function of Chimeric Human IgG4-S228P Isotype Control mAb

For more references about Chimeric Human IgG4-S228P Isotype Control Antibody, please contact our scientific support team with message@sydlabs.com.

Syd Labs provides the following IgG Protein :
Human IgG1 Fc Protein
Human IgG1 Fc Protein
Human IgG2 Fc Protein
Human IgG3 Fc Protein
Human IgG4 Fc Protein
Llama IgG2b Fc Protein
Mouse IgG1 Fc Protein
Mouse IgG2a Fc Protein
Mouse IgG2b Fc Protein
Mouse IgG2c Fc Protein
Mouse IgG2C Protein
Mouse IgG3 Fc Protein
Rabbit IgG Protein
Rat IgG2a Fc Protein
Rat IgG2b Fc Protein

Home

Services

Molecular Biology

Proteins & Peptides

Antibodies

ELISA Kits

Chemicals

Cell Biology

Contact

My Syd Labs

Email Notifications

Chimeric Human IgG4-S228P Isotype Control Antibody

Chimeric hIgG4 Isotype Control, Chimeric Human IgG4 Isotype Control, Chimeric hIgG4 S228P

Note

Note

Order Offline

PA007194: In Vivo Grade Recombinant Chimeric Human IgG4-S228P kappa Isotype Control Antibody (Chimeric IgG4-S228P Isotype Control)

PA007195: In Vivo Grade Recombinant Chimeric Human IgG4-S228P L235E P329G kappa Isotype Control Antibody (Chimeric hIgG4-SPLEPG Isotype Control)

References of Chimeric Human IgG4-S228P Isotype Control Antibody: